Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stomach Neoplasms | 10 | 2020 | 1424 | 2.520 |
Why?
|
Lymph Nodes | 7 | 2018 | 3486 | 1.140 |
Why?
|
Gastrectomy | 4 | 2018 | 679 | 0.980 |
Why?
|
Adenocarcinoma | 5 | 2020 | 6316 | 0.880 |
Why?
|
Neoadjuvant Therapy | 5 | 2020 | 2821 | 0.850 |
Why?
|
Pancreatic Neoplasms | 6 | 2020 | 5349 | 0.840 |
Why?
|
Lymph Node Excision | 5 | 2020 | 1303 | 0.770 |
Why?
|
Pancreatectomy | 4 | 2020 | 810 | 0.680 |
Why?
|
Hydroxyprostaglandin Dehydrogenases | 1 | 2018 | 31 | 0.630 |
Why?
|
Neuroendocrine Tumors | 3 | 2018 | 650 | 0.580 |
Why?
|
Standard of Care | 1 | 2019 | 552 | 0.520 |
Why?
|
Chemoprevention | 1 | 2018 | 326 | 0.520 |
Why?
|
Cyclooxygenase 2 | 1 | 2018 | 599 | 0.510 |
Why?
|
Adenoma | 2 | 2018 | 2148 | 0.500 |
Why?
|
Neoplasm Staging | 10 | 2019 | 11152 | 0.460 |
Why?
|
Carcinoma, Pancreatic Ductal | 3 | 2020 | 1722 | 0.450 |
Why?
|
Anticarcinogenic Agents | 2 | 2013 | 249 | 0.440 |
Why?
|
SEER Program | 6 | 2018 | 1530 | 0.420 |
Why?
|
Colonic Neoplasms | 3 | 2009 | 2526 | 0.410 |
Why?
|
Pancreaticoduodenectomy | 3 | 2020 | 508 | 0.400 |
Why?
|
Neoplasm Invasiveness | 6 | 2018 | 3618 | 0.360 |
Why?
|
Carcinoma | 1 | 2020 | 2331 | 0.320 |
Why?
|
Liver Neoplasms | 6 | 2020 | 4319 | 0.290 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2020 | 9278 | 0.280 |
Why?
|
Mortality | 1 | 2018 | 2916 | 0.280 |
Why?
|
Laparoscopy | 1 | 2018 | 2147 | 0.270 |
Why?
|
Combined Modality Therapy | 5 | 2020 | 8552 | 0.260 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2019 | 1791 | 0.250 |
Why?
|
Hepatectomy | 2 | 2020 | 559 | 0.240 |
Why?
|
Proportional Hazards Models | 9 | 2020 | 12531 | 0.240 |
Why?
|
Length of Stay | 1 | 2018 | 6476 | 0.240 |
Why?
|
Survival Rate | 9 | 2020 | 12810 | 0.230 |
Why?
|
Databases, Factual | 5 | 2019 | 8022 | 0.230 |
Why?
|
Survival Analysis | 6 | 2019 | 10185 | 0.230 |
Why?
|
Patient Readmission | 1 | 2018 | 3322 | 0.230 |
Why?
|
Aged | 31 | 2020 | 169143 | 0.230 |
Why?
|
Carcinoma, Hepatocellular | 4 | 2020 | 2299 | 0.230 |
Why?
|
Prognosis | 12 | 2020 | 29661 | 0.230 |
Why?
|
Breast Diseases | 2 | 2004 | 443 | 0.230 |
Why?
|
Retroperitoneal Neoplasms | 2 | 2017 | 329 | 0.230 |
Why?
|
Aged, 80 and over | 15 | 2020 | 58980 | 0.220 |
Why?
|
Sulfonamides | 1 | 2013 | 1977 | 0.220 |
Why?
|
Hepatitis B | 2 | 2020 | 701 | 0.220 |
Why?
|
Pyrazoles | 1 | 2013 | 1999 | 0.210 |
Why?
|
Middle Aged | 34 | 2020 | 220359 | 0.210 |
Why?
|
Lymphatic Metastasis | 4 | 2018 | 2943 | 0.200 |
Why?
|
Male | 35 | 2020 | 359718 | 0.190 |
Why?
|
Female | 40 | 2020 | 391246 | 0.190 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2019 | 3530 | 0.190 |
Why?
|
Sarcoma | 3 | 2017 | 1786 | 0.190 |
Why?
|
Chemoembolization, Therapeutic | 2 | 2020 | 127 | 0.180 |
Why?
|
Age Factors | 6 | 2019 | 18413 | 0.180 |
Why?
|
Peripheral Vascular Diseases | 3 | 2008 | 515 | 0.180 |
Why?
|
Sorting Nexins | 1 | 2020 | 27 | 0.180 |
Why?
|
Peptide Elongation Factor 1 | 1 | 2020 | 39 | 0.170 |
Why?
|
Retrospective Studies | 20 | 2020 | 80345 | 0.170 |
Why?
|
Colorectal Neoplasms | 3 | 2020 | 6853 | 0.160 |
Why?
|
Quality Indicators, Health Care | 1 | 2009 | 1822 | 0.160 |
Why?
|
Treatment Outcome | 10 | 2020 | 64981 | 0.160 |
Why?
|
Humans | 46 | 2020 | 760613 | 0.150 |
Why?
|
Colon | 2 | 2017 | 1788 | 0.150 |
Why?
|
Portal Vein | 1 | 2020 | 429 | 0.140 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2004 | 1096 | 0.140 |
Why?
|
Myeloid Cells | 1 | 2020 | 821 | 0.130 |
Why?
|
Vascular Surgical Procedures | 4 | 2008 | 1469 | 0.130 |
Why?
|
Taiwan | 1 | 2017 | 505 | 0.130 |
Why?
|
United States | 8 | 2020 | 72448 | 0.120 |
Why?
|
Adrenal Glands | 1 | 2017 | 554 | 0.120 |
Why?
|
Hospitals, University | 1 | 2017 | 568 | 0.120 |
Why?
|
Ubiquitin | 1 | 2020 | 838 | 0.120 |
Why?
|
Hemangiosarcoma | 1 | 2017 | 216 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 4 | 2018 | 6544 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2020 | 995 | 0.120 |
Why?
|
China | 1 | 2020 | 2339 | 0.120 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 15790 | 0.110 |
Why?
|
Hepatocyte Nuclear Factor 3-beta | 1 | 2013 | 64 | 0.110 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1313 | 0.110 |
Why?
|
Receptor, erbB-3 | 1 | 2014 | 143 | 0.110 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2017 | 547 | 0.110 |
Why?
|
Estrogen Receptor beta | 1 | 2013 | 168 | 0.100 |
Why?
|
Tumor Burden | 1 | 2018 | 1895 | 0.100 |
Why?
|
Receptor, IGF Type 1 | 1 | 2014 | 380 | 0.100 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2016 | 586 | 0.100 |
Why?
|
Multivariate Analysis | 3 | 2018 | 12159 | 0.100 |
Why?
|
Cadherins | 1 | 2016 | 898 | 0.090 |
Why?
|
Endosonography | 1 | 2015 | 607 | 0.090 |
Why?
|
Extremities | 2 | 2014 | 867 | 0.090 |
Why?
|
Iodine Radioisotopes | 1 | 2014 | 1032 | 0.090 |
Why?
|
Risk Assessment | 8 | 2019 | 24102 | 0.090 |
Why?
|
Receptor, Insulin | 1 | 2014 | 836 | 0.090 |
Why?
|
Cholangiocarcinoma | 1 | 2016 | 548 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2014 | 567 | 0.090 |
Why?
|
Dermatofibrosarcoma | 1 | 2010 | 48 | 0.090 |
Why?
|
Adult | 20 | 2020 | 220007 | 0.090 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 936 | 0.080 |
Why?
|
Catheter Ablation | 2 | 2017 | 2758 | 0.080 |
Why?
|
Estrogen Receptor alpha | 1 | 2013 | 580 | 0.080 |
Why?
|
Postoperative Complications | 4 | 2020 | 15679 | 0.080 |
Why?
|
Liver Transplantation | 1 | 2020 | 2325 | 0.080 |
Why?
|
Disease-Free Survival | 3 | 2020 | 6831 | 0.080 |
Why?
|
Linkage Disequilibrium | 1 | 2013 | 1996 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2018 | 2754 | 0.080 |
Why?
|
Young Adult | 6 | 2018 | 58748 | 0.070 |
Why?
|
Tumor Microenvironment | 1 | 2020 | 3844 | 0.070 |
Why?
|
Mohs Surgery | 1 | 2010 | 221 | 0.070 |
Why?
|
Proctoscopy | 1 | 2007 | 40 | 0.070 |
Why?
|
Preoperative Care | 2 | 2015 | 2255 | 0.070 |
Why?
|
Hepatitis B, Chronic | 1 | 2011 | 403 | 0.070 |
Why?
|
Registries | 2 | 2017 | 8458 | 0.070 |
Why?
|
Breast Neoplasms | 4 | 2017 | 21029 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2015 | 2829 | 0.070 |
Why?
|
Brachytherapy | 1 | 2014 | 1238 | 0.070 |
Why?
|
Probability | 2 | 2009 | 2475 | 0.070 |
Why?
|
Prospective Studies | 4 | 2018 | 54306 | 0.060 |
Why?
|
Transforming Growth Factor beta | 1 | 2013 | 1959 | 0.060 |
Why?
|
Carcinoid Tumor | 1 | 2007 | 228 | 0.060 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 2802 | 0.060 |
Why?
|
Germ-Line Mutation | 1 | 2013 | 1842 | 0.060 |
Why?
|
Sputum | 1 | 2007 | 503 | 0.060 |
Why?
|
Skin Neoplasms | 2 | 2017 | 5799 | 0.060 |
Why?
|
Limb Salvage | 1 | 2007 | 465 | 0.060 |
Why?
|
Saphenous Vein | 1 | 2007 | 537 | 0.060 |
Why?
|
Vascular Patency | 1 | 2007 | 901 | 0.060 |
Why?
|
Logistic Models | 1 | 2018 | 13312 | 0.060 |
Why?
|
Antigens, CD | 1 | 2014 | 4000 | 0.060 |
Why?
|
Pneumonia, Ventilator-Associated | 1 | 2007 | 278 | 0.060 |
Why?
|
Macula Lutea | 1 | 2005 | 169 | 0.060 |
Why?
|
Paroxetine | 1 | 2004 | 182 | 0.050 |
Why?
|
Estrogen Receptor Modulators | 1 | 2003 | 58 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2013 | 10343 | 0.050 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2005 | 250 | 0.050 |
Why?
|
Kidney | 1 | 2017 | 7064 | 0.050 |
Why?
|
Follow-Up Studies | 5 | 2017 | 39262 | 0.050 |
Why?
|
Cohort Studies | 3 | 2020 | 41337 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 11713 | 0.050 |
Why?
|
Nerve Fibers | 1 | 2005 | 708 | 0.050 |
Why?
|
Optic Disk | 1 | 2005 | 421 | 0.040 |
Why?
|
Analysis of Variance | 1 | 2009 | 6238 | 0.040 |
Why?
|
Ligation | 1 | 2020 | 448 | 0.040 |
Why?
|
Lower Extremity | 1 | 2007 | 1193 | 0.040 |
Why?
|
Retinal Ganglion Cells | 1 | 2005 | 805 | 0.040 |
Why?
|
Genes, Neoplasm | 1 | 2020 | 370 | 0.040 |
Why?
|
Irritable Bowel Syndrome | 1 | 2004 | 453 | 0.040 |
Why?
|
Rectal Neoplasms | 1 | 2007 | 1152 | 0.040 |
Why?
|
Carcinoma in Situ | 1 | 2004 | 796 | 0.040 |
Why?
|
Tamoxifen | 1 | 2003 | 963 | 0.040 |
Why?
|
Protein Stability | 1 | 2020 | 566 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 2002 | 2222 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14661 | 0.030 |
Why?
|
Doxorubicin | 1 | 2002 | 2208 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2013 | 22052 | 0.030 |
Why?
|
MicroRNAs | 1 | 2011 | 3787 | 0.030 |
Why?
|
Adrenalectomy | 1 | 2017 | 348 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2009 | 15286 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2016 | 17790 | 0.030 |
Why?
|
Depressive Disorder | 1 | 2008 | 3726 | 0.030 |
Why?
|
Sex Factors | 1 | 2009 | 10546 | 0.030 |
Why?
|
New York | 2 | 2008 | 875 | 0.030 |
Why?
|
DNA, Neoplasm | 1 | 2020 | 1745 | 0.030 |
Why?
|
Glaucoma | 1 | 2005 | 1182 | 0.030 |
Why?
|
Morbidity | 1 | 2020 | 1765 | 0.030 |
Why?
|
Hepatitis B virus | 1 | 2018 | 522 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2013 | 12628 | 0.030 |
Why?
|
Aberrant Crypt Foci | 1 | 2013 | 12 | 0.030 |
Why?
|
Pancreas | 1 | 2020 | 1677 | 0.030 |
Why?
|
Mice, Nude | 1 | 2020 | 3607 | 0.030 |
Why?
|
Paneth Cells | 1 | 2013 | 98 | 0.030 |
Why?
|
Coronary Disease | 1 | 2008 | 5991 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2020 | 2192 | 0.030 |
Why?
|
Smad4 Protein | 1 | 2013 | 191 | 0.030 |
Why?
|
Incidence | 2 | 2017 | 21391 | 0.030 |
Why?
|
Colectomy | 1 | 2017 | 692 | 0.030 |
Why?
|
Propensity Score | 1 | 2020 | 1926 | 0.030 |
Why?
|
Nephrectomy | 1 | 2017 | 1016 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20509 | 0.020 |
Why?
|
Tomography, Optical Coherence | 1 | 2005 | 2884 | 0.020 |
Why?
|
Mastectomy, Segmental | 1 | 2017 | 972 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3583 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2017 | 2852 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 22075 | 0.020 |
Why?
|
Apoptosis | 2 | 2020 | 9497 | 0.020 |
Why?
|
Biopsy | 1 | 2003 | 6771 | 0.020 |
Why?
|
Risk Factors | 5 | 2020 | 74333 | 0.020 |
Why?
|
ROC Curve | 2 | 2011 | 3568 | 0.020 |
Why?
|
Up-Regulation | 1 | 2020 | 4122 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2020 | 16932 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2013 | 1754 | 0.020 |
Why?
|
Algorithms | 2 | 2008 | 13982 | 0.020 |
Why?
|
Safety | 1 | 2014 | 1148 | 0.020 |
Why?
|
Frozen Sections | 1 | 2010 | 153 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2007 | 15840 | 0.020 |
Why?
|
Hedgehog Proteins | 1 | 2013 | 769 | 0.020 |
Why?
|
Signal Transduction | 3 | 2020 | 23374 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2007 | 7408 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2018 | 4902 | 0.020 |
Why?
|
Quinazolines | 1 | 2014 | 1363 | 0.020 |
Why?
|
Gentian Violet | 1 | 2007 | 29 | 0.020 |
Why?
|
Graft Rejection | 1 | 2020 | 4426 | 0.020 |
Why?
|
Phenazines | 1 | 2007 | 56 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 4108 | 0.020 |
Why?
|
Depression | 1 | 2007 | 8045 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2016 | 2013 | 0.020 |
Why?
|
Disease Management | 1 | 2017 | 2514 | 0.020 |
Why?
|
Time Factors | 2 | 2007 | 40139 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2020 | 11070 | 0.020 |
Why?
|
Venous Insufficiency | 1 | 2007 | 111 | 0.020 |
Why?
|
Popliteal Artery | 1 | 2008 | 312 | 0.020 |
Why?
|
Hospitals, Veterans | 1 | 2008 | 398 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2010 | 1008 | 0.020 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2007 | 748 | 0.020 |
Why?
|
Immunotherapy | 1 | 2020 | 4642 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2020 | 10442 | 0.010 |
Why?
|
Receptor, erbB-2 | 1 | 2014 | 2554 | 0.010 |
Why?
|
Femoral Artery | 1 | 2008 | 831 | 0.010 |
Why?
|
Leg | 1 | 2008 | 1091 | 0.010 |
Why?
|
Intestinal Mucosa | 1 | 2013 | 3022 | 0.010 |
Why?
|
Visual Field Tests | 1 | 2005 | 411 | 0.010 |
Why?
|
Diagnostic Tests, Routine | 1 | 2008 | 786 | 0.010 |
Why?
|
Treatment Failure | 1 | 2007 | 2647 | 0.010 |
Why?
|
Medical Records Systems, Computerized | 1 | 2007 | 1191 | 0.010 |
Why?
|
Area Under Curve | 1 | 2005 | 1635 | 0.010 |
Why?
|
Stem Cells | 1 | 2013 | 3524 | 0.010 |
Why?
|
Dietary Fiber | 1 | 2004 | 760 | 0.010 |
Why?
|
Mice | 2 | 2020 | 81209 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2016 | 8512 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2014 | 5251 | 0.010 |
Why?
|
Adolescent | 3 | 2017 | 87809 | 0.010 |
Why?
|
Disease Progression | 1 | 2016 | 13505 | 0.010 |
Why?
|
Intraocular Pressure | 1 | 2005 | 1288 | 0.010 |
Why?
|
Visual Fields | 1 | 2005 | 1054 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2011 | 3202 | 0.010 |
Why?
|
Reference Values | 1 | 2004 | 4925 | 0.010 |
Why?
|
Anesthesia | 1 | 2008 | 1584 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2004 | 4899 | 0.010 |
Why?
|
Head and Neck Neoplasms | 1 | 2010 | 2882 | 0.010 |
Why?
|
Mutation | 1 | 2020 | 29957 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2011 | 9406 | 0.010 |
Why?
|
Odds Ratio | 1 | 2008 | 9716 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2013 | 22020 | 0.010 |
Why?
|
Animals | 2 | 2020 | 167960 | 0.010 |
Why?
|
Recurrence | 1 | 2007 | 8483 | 0.010 |
Why?
|
Intensive Care Units | 1 | 2007 | 3736 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10826 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2004 | 12427 | 0.010 |
Why?
|
Prevalence | 1 | 2007 | 15686 | 0.010 |
Why?
|
Stroke | 1 | 2008 | 9952 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 2005 | 25941 | 0.000 |
Why?
|